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Company Name Kite Pharma, Inc. 
Date 12/8/16 
Current Price $45.07 
2016 Fiscal Year End 12/31/16 (Currently in Q4) 
52 Week Range $38.41-$69.50 
Market Cap $2,247.9 Billion 
Enterprise Value $1,770.8 Billion 
Total Debt $0 
Cash $477.1 Million 
Dividend N/A 
Diluted Shares Outstanding 49,624,622 
2017 EPS (Est.)* -$5.67 
2016 EPS (Est.)* -$4.46 
2015 EPS -$2.33 
2014 EPS -$1.91 
2013 EPS -$1.43 
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 Kite Pharma, Inc. is a pre-profit biotechnology company focused on developing 
genetically engineered T-cell therapies designed to target and remove cancerous cells. 
Using a proprietary discounted net present value (NPV) model, assumptions based on 
the Federal Drug Administration (FDA) approval timeline, independent analysis of 
market share penetration, and management guidance, we have concluded that Kite 
Pharma is undervalued with a potential upside of 89.25% based on the target price of 
$85.30.  Despite the large amount of uncertainty regarding the FDA approval process, 
our analysis anticipates that Kite Pharma’s lead product KTE-C19 will receive FDA 
approval for treatment of relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) 
based on positive clinical trial results in a patient population with no further treatment 
options.  Additionally, the T-cell therapy may provide a general platform for treatment 
of other ailments not explicitly included in our NPV analysis.  Ultimately, we recommend 
Kite Pharma a BUY with a target price of $85.30.  
 
Catalysts and Risks: 
 
• Kite Pharma’s leading product (KTE-C19) has received breakthrough therapy and 
orphan drug designations from the FDA and the European Medicines Agency 
(EMA). 
• Positive interim data in the ZUMA-1 Phase 2/3 clinical trial were reported in 
September 2016. 
• A rolling Biologics License Application (BLA) has been submitted to the FDA for 
KTE-C19 for relapsed/refractory DLBCL.  BLA submission is expected to be 
completed during the first quarter of 2017. 
• KTE-C19 has the potential to be a first to market product (i.e. the first to begin 
BLA submission process for an engineered T-cell therapy). 
• Several clinical and pre-clinical products in the pipeline are advancing in 
development. 
• Numerous partnerships and collaborations dedicated to increasing research and 
development efforts have been forged. 
• Kite Pharma has purchased a facility in El Segundo, CA designated for 
manufacturing T-cells therapies in preparation for commercialization. 
• Severe side effects in patients receiving treatment with KTE-C19 have been 
reported during clinical trials, which may influence the FDA’s recommendation. 
• FDA approval is not guaranteed.  It is dependent upon drug efficacy, and the 
ability to successfully and safely manufacture the therapy. 
• There is significant competition from other companies developing the same or 
similar technologies. 
• Political agendas against high pharmaceutical pricing may affect the company 
and the biotechnology sector. 
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Company Overview:  
 
  Kite Pharma, Inc. is a pre-profit biotechnology company developing novel cancer 
immunotherapies through genetically engineering a patient’s own immune system to 
specifically target cancerous cells.  Kite Pharma was incorporated in June 2009 in 
Delaware and is currently headquartered in Santa Monica, CA.  The company went 
public on June 20th, 2014 and began trading under the ticker KITE on the Nasdaq Stock 




Kite Pharma is developing two types of engineered T-cell therapies: Chimeric 
Antigen Receptor (CAR) and T-cell Receptor (TCR) T-cells.  Their pipeline boasts several 
candidates that are already in clinical trials or are close to being filed as investigational 
new drugs (IND) as summarized in Figure 1.  
KTE-C19, Kite Pharma’s lead product, is currently in Phase 1/2 and 2/3 clinical 
trials and has been granted breakthrough therapy and orphan drug status by the FDA 
and EMA to treat aggressive forms of relapsed/refractory Non Hodgkin Lymphoma 
(NHL).  The breakthrough therapy designation allowed Kite Pharma to begin filing a 
rolling BLA on December 4th, 2016, and grants an accelerated review process from the 
FDA.  This priority review status may give KTE-C19 an advantage in the race to be the 
first engineered T-cell therapy to market.  Additionally, orphan drug status may grant 
Kite Pharma financial subsidization for clinical research, tax incentives, and extended 




Figure 1. Kite Pharma (Nasdaq: KITE) Pipeline for CAR and TCR T-cell Therapies 
(Source: Kite Pharma, Inc. 2015 10K) 
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Acquisitions, Collaborations, and Partnerships 
 
Kite Pharma has strategically positioned themselves to ensure that they will be 
capable of manufacturing their products upon FDA approval.  The company has secured 
two locations for clinical manufacturing: one in Santa Monica, CA and one in El Segundo, 
CA. 1  Both of these facilities have been furnished with state of the art equipment and 
will serve as the base of operations for clinical manufacturing.  The El Segundo facility 
opened in June 2016 and it is scheduled to be operational for commercialization of KTE-
C19 prior to its expected FDA approval in 2017. 2  Additionally, Kite Pharma has 
collaborated with General Electric to develop an integrated and automated device for 
streamlining their T-cell therapy manufacturing method to ensure it is effective, 
consistent, and safe.  Kite Pharma has also recently announced a deal with Vitruvian 
Networks to develop an integrated platform for patients, physicians, and treatment 
centers to help coordinate the logistics for treatment with their therapies, allowing a 
seamless form of communication between all relevant parties during a patient’s 
treatment. 
In an effort to support their research and development (R&D) efforts, Kite 
Pharma entered a stock purchase agreement to acquire all outstanding shares of the T-
Cell Factory (TCF), renamed Kite Pharma EU B.V., on March 17, 2015 for $21 million, 
making TCF a wholly owned subsidiary.3  TCF has developed a novel platform for 
discovering unique tumor antigens for T-cell receptor (TCR) therapies and Kite Pharma 
plans to use this technology to expand their pipeline of TCR products.  The company has 
made numerous additional collaborations and partnerships to support their R&D efforts, 
including multiple cooperative research and development agreements with the National 
Cancer Institute, collaborations with major pharmaceutical companies Amgen and 
Genentech, and a partnership with Cell Design Labs to improve the design and safety of 
their CAR T-cell products.  A full list of their collaborations and partnerships is detailed in 
Appendix A.  What is clear from this analysis is that Kite Pharma has taken multiple steps 
to ensure commercial success at scale and is not attempting to simply bring a drug to 
approval for a larger company to buy them out.  This foresight by management 






                                                        
1 Kite Pharma, Inc. (February 19th, 2015). Kite Pharma Establishes Manufacturing Capabilities to Support Development 
and Commercialization of CAR and TCR Cancer Immunotherapy Products. [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?releaseid=897155 
2 Kite Pharma, Inc. (June 20th, 2016). Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility. [Press 
Release].  Retrieved from: http://ir.kitepharma.com/releasedetail.cfm?releaseid=976420 
3 Kite Pharma paid approximately $15.1 million in cash and issued $4.2 million in shares of common stock 
(66,120 share).  Approximately €2 million was withheld from sellers to satisfy potential indemnity claims, and will 
be repaid at the close of the 18 month indemnity hold back period.  





eACT Design and Manufacturing: 
 
 Kite Pharma has developed two types of engineered autologous cell therapies 
(eACT): Chimeric Antigen Receptors (CAR) and T-Cell Receptors (TCR). Both therapies 
involve engineering a patient’s own T-cells to target their tumor, and each method has 
advantages and disadvantages.  CARs are capable of recognizing antigens on the surface 
of cancer cells and do not rely on MHC (major histocompatibility complex) presentation 
(Figure 2).  Therefore, they do not require the therapy to be matched to the patient’s 
HLA (human leukocyte antigen) type making them universal.  TCRs require an antigen to 
be presented by MHC, but are capable of recognizing internal antigens and allow for the 
scope of potential targets to widen (Figure 2).  Additionally, TCRs are capable of 
recognizing antigens presented by other immune cells, which can further stimulate the 




Figure 2. Kite Pharma (Nasdaq: KITE) Design for CAR-engineered T-cells (left panel) and TCR-engineered T-cells (right panel) 
(Source: Kite Pharma Inc. (2015) 10K) 
 
Manufacturing T-cell therapies is complicated and requires a patient’s blood 
sample to be shipped to a separate facility for processing (Figure 3).  The patient’s T-
cells are isolated, activated, and infused with either a CAR or TCR gene.  The engineered 
T-cells are then expanded and shipped back to the patient for treatment.  Altogether, 
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Kite Pharma states this process takes up to two weeks and the company has reported a 
97% success rate thus far.4  In June 2016, Kite Pharma opened their state of the art 
facility for commercial manufacturing in El Segundo, CA.  The company estimates that 




Figure 3. Kite Pharma (Nasdaq: KITE) manufacturing process for eACT 




 Kite Pharma’s lead product (KTE-C19) is a CAR T-cell therapy that targets the cell 
surface antigen CD-19, which is found on B-cell lymphomas and leukemias.  The patients 
currently being tested in clinical trials have all failed treatment with at least one therapy 
prior to enrollment.  The standard treatment for patients diagnosed with DLBCL, the 
most common form of NHL, is a chemotherapy regiment called R-CHOP.6  If complete 
remission is achieved after treatment, patients may be eligible to undergo a potentially 
curative stem cell transplant.  However, some patients never reach complete remission 
and do not qualify for a stem cell transplant.  Other patients have recurrences of disease 
despite initially responding to treatment even after receiving a stem cell transplant in 
some cases.  Some of these patients eventually become refractive to all available 
therapies and are considered to have relapsed and refractory disease with no further 
efficacious treatment options.  CAR T-cell therapy offers these patients another chance 
for remission, and possibly another opportunity for a curative stem cell transplant.   
 In addition to DLBCL, KTE-C19 is being tested in other forms of 
relapsed/refractory NHL.  These include Primary Mediastinal B-Cell Lymphoma (PMBCL), 
Transformed Follicular Lymphoma (TFL), Mantle Cell Lymphoma (MCL), and acute 
Lymphoblastic Leukemia (ALL).  Kite Pharma is also testing CAR and TCR T-cell therapies 
                                                        
4 Kite Pharma Inc. (October 18th, 2016). Investor Day: Focused on the Cure. Slide 88 
5 Kite Pharma Inc. (June 20th, 2016). Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility. [Press 
Release]. Retrieved from: http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=976420 
6 Roschewski, M. et al. Diffuse large B-cell lymphoma- treatment approaches in the molecular era. Nat Rev Clin Onc. 
11, 12-23 (2014). 
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that target different antigens specific for other forms of blood cancers and solid tumors 
(Figure 1).  
 
Clinical Trial Results: 
   
KTE-C19 for Chemorefractory DLBCL, PMBCL, TFL (ZUMA-1) 
 
 KTE-C19 is currently being tested in a Phase 2/3 trial in patients with aggressive 
forms of relapsed/refractory NHL, including DLBCL, PMBCL and TFL.  In September 2016, 
Kite Pharma released interim results for its ZUMA-1 clinical trial and presented data at 
the annual American Society for Hematology (ASH) meeting in December 2016 (Figure 
4).7  KTE-C19 achieved an objective response rate8 (ORR) of 76% and a complete 
response9 (CR) of 47% in DLBCL.  By month 3, those rates drop to 39% for ORR and 33% 
for CR. In PMBCL and TFL, the results were even more striking, with 64% of patients 
achieving and ORR and CR at 3 months post treatment.  The data for 6 and 9 months 
post treatment are expected by March of 2017.  Based on these promising results, Kite 
Pharma began a rolling submission of a BLA to the FDA for KTE-C19 in 
relapsed/refractory NHL on December 4th, 2016.10  Management expects the BLA to be 




Figure 4. Interim results from KTE-C19 ZUMA-1 Clinical Trial 
(Source: Kite Pharma Inc. (September 26th, 2016). Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-
1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL). [Press Release]) 
 
                                                        
7 Kite Pharma Inc. (September 26th, 2016).  Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 
Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL). [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=990947 
8 The overall response rate (ORR) is the proportion of patients with a reduction in tumor size of a predefined amount 
over a minimum period of time.  In this trial, patients were said to reach ORR if they had a reduction in tumor volume 
or either a partial response or a complete response at 3 months post treatment with KTE-C19. Source: 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071590.pdf 
9 Complete response (CR) is defined by the absence of tumor.  In this trial, patients were said to reach CR if there was 
no evidence of tumor cells at 3 months post treatment with KTE-C19.  Source: 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071590.pdf 
10 Kite Pharma Inc. (December 4th, 2016). Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application 
(BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with 
Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL). [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=1002522 
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KTE-C19 for Relapsed/Refractory MCL (ZUMA-2) 
 
 At this time, Kite Pharma has not released any data from patients enrolled in the 
Phase 2 ZUMA-2 clinical trial for Mantle Cell Lymphoma (MCL), which is currently still 
enrolling patients.  Interim clinical trial results are expected in 2017.   
 
KTE-C19 for Adult and Pediatric Relapsed/Refractory ALL (ZUMA-3 and ZUMA-4) 
 
 KTE-C19 is also being tested in a Phase 1/2 trial in adult and pediatric patients 
with relapsed/refractory ALL. The data were presented at the annual ASH meeting in 
December of 2016.  9/11 patients, 82%, had complete remission during preliminary 
analysis and 100% tested negative for minimal residual disease.11  38% of patients 
experienced severe cytokine release syndrome and neurological effects.  Kite Pharma 




As detailed above, Kite Pharma has seen remarkable success in patient 
populations that have no alternate therapies.  However, a significant number of patients 
have exhibited serious side effects, including cytokine release syndrome (CRS) and 
severe neurologic effects (NE).12  CRS occurs as a result of over-stimulating the immune 
system, causing systemic symptoms such as high fever, nausea, hypotension (low blood 
pressure), dyspnea (difficult breathing), and tachycardia (fast heart-rate).  These 
symptoms can range from mild to life threatening.  The neurological effects that have 
been reported include confusion, delirium, and seizures; the cause of these effects is not 
yet known.  These side effects have been manageable by closely monitoring patients 
and dampening the immune response with steroids when necessary.  Despite the risk of 
adverse effects, a majority of physicians have reported that they would still recommend 
CAR T-cell therapy since there are currently no other treatment options available for 
these patient populations.13 
Kite Pharma reported in its ZUMA-1 trial that 29% of patients exhibited CRS and 
13% exhibited NE.14  Three patients have died during the trial, but not due to these side 
effects.  Kite Pharma has reported no cases of cerebral edema in any of their trials to 
date.  In contrast, there have been several deaths in patients enrolled in competitor’s 
                                                        
11 Kite Pharma Inc. (December 4th, 2016). Kite Pharma Reports 82 percent of Patients Achieved Complete Remission in 
Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High 
Burden Relapsed/Refractory Acute Lymphoblastic Leukemia. [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=1002521  
12 Bonifant, C.L. et al. Toxicity and Management in CAR T-cell Therapy. Mol Ther Oncolytics. 3, 16011 (2016). 
13 Kite Pharma Inc. (October 18th, 2016) Investor Day: Focused on the Cure. Slide 103. 
14 Kite Pharma Inc. (September 26th, 2016). Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 
Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL). [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=990947 
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Juno Therapeutics’ Phase 2 ROCKET trial as a result of cerebral edema, prompting Juno 
to voluntarily suspend their trial until the cause can be investigated further.15  
In response to the severe side effects observed, Kite Pharma has begun 
developing safety measures to incorporate into their future engineered CAR T-cell 
therapies.  One of these modifications includes a molecular control switch that would 
allow physicians to kill the engineered CAR T-cells if severe side effects occur.16  This 
process would be reversible, allowing the remaining T-cells to continue attacking the 
tumor after the side effects have subsided.  KITE-796 is the first product developed to 




 There are several companies in addition to Kite Pharma that are involved in 
developing CAR and TCR engineered T-cells, including Novartis (NYSE: NVS), Juno 
Therapeutics (Nasdaq: JUNO), and bluebird bio (Nasdaq: BLUE).   
Novartis’ candidate CTL019 is the closest to reaching FDA approval.  CTL019 is 
also a CAR engineered T-cell designed to target CD19 and has been tested in patients 
with relapsed/refractory adult and pediatric ALL and relapsed/refractory DLBCL; the 
clinical trial results have been promising and comparable to Kite Pharma’s ZUMA-1 
trial.18  CTL019 has been designated a breakthrough therapy by the FDA and Novartis 
plans to file a BLA in early 2017 for ALL with a BLA for DLBCL to follow later on in the 
year.  Since the timeline for approval is similar to KTE-C19, and the diseases being tested 
are the same, Novartis poses the biggest threat to Kite Pharma’s success.  
Juno Therapeutics has recently suspended its Phase 2 ROCKET trial after 5 
patient deaths linked to their JCAR015 CAR T-cell therapy.19  Thirty-eight people have 
been treated with JCAR015, making their treatment mortality rate a high 13%.  It is 
unclear if Juno will seek to continue developing JCAR015 or if it will cease to develop the 
product altogether.  Juno Therapeutics released positive Phase 1 data on its other 
leading product JCAR017 in the TRANSCEND trial, which also targets CD19 in ALL and 
                                                        
15 Juno Therapeutics. {November 23rd, 2016). Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical 
Hold. [Press Release]. Retrieved from: http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-
newsArticle&ID=2225491 
16 Kite Pharma Inc. (June 2nd, 2016). Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration 
Using Molecular ‘On/Off Switches’ for CAR T-cell Immunotherapies. [Press Release]. Retrieved from: 
http://ir.kitepharma.com/releasedetail.cfm?releaseid=973947 
17 Kite Pharma Inc. (October 18th, 2016) Investor Day: Focused on the Cure. Slide 13. 
18 Novartis. (December 6th, 2015). Novartis Announces New CTL019 Study Data Demonstrating Overall Response in 
Adult Patients with Certain Types of Lymphoma. [Press Release]. Retrieved from: 
https://www.novartis.com/news/media-releases/novartis-announces-new-ctl019-study-data-demonstrating-overall-
response-adult 
19 Juno Therapeutics. (November 23rd, 2016). Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold. 
[Press Release]. Retrieved from: http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-
newsArticle&ID=2225491 
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DLBCL, that were comparable to Kite Pharma’s KTE-C19 results.20  However, at this 
point, Juno Therapeutics is at least a year behind Kite Pharma in the race to FDA 
approval.  
 Bluebird bio, partnered with Celgene (Nasdaq: CELG), has several T-cell therapies 
in the early stages of development.  The interim results from a Phase 1 trial were 
recently released for their leading candidate bb2121, a CAR T-cell that targets B-Cell 
Maturation Antigen (BCMA).  Bb2121 is being tested in Multiple Myeloma (MM). 100% 
of the 6 patients in the second and third dose cohort reached the objective response 
rate, and 2 patients had no evidence of disease at 4 and 6 month follow ups.21  
Importantly, none of the patients developed severe side effects such as cytokine release 
syndrome or neurological toxicities, making these early data the most compelling seen 
for any CAR T-cell therapy to date.  Kite Pharma is currently in the pre-clinical stage of 
development for its candidate KTE-585, which is being developed to target BCMA in 
MM, and plans to file an IND application sometime during 2017.22  Currently, this puts 
Kite Pharma behind in the race for MM therapies in development.  However, the 
company is much more established when it comes to manufacturing capabilities due to 
its progress in preparing to advance KTE-C19 to market, which may provide an edge 




 Pre-profit biotechnology companies are commonly prone to volatility in market 
prices due to their high risk of failure. Thus, Kite Pharma has been subject to large price 
swings especially since they are developing a therapy that has no FDA approved 
equivalent.  The uncertainty in commercial success for engineered T-cell therapy has 
contributed to frequent changes in the stock price often driven by press releases for 
clinical trial results or FDA announcements from either Kite Pharma or any of its 
competitors.  In addition, there has been an overall downward trend in the biotech 
sector beginning in late 2015 and continuing throughout much of 2016 (Figure 5).  
 The healthcare industry has also recently faced considerable political headwinds 
in response to concerns about overpriced drugs.  There have been several calls for 
increased regulation to prevent pharmaceutical companies from inflating their drug 
prices to boost revenues, especially for drugs that are life saving and necessary for a 
patient’s health.  As a result, the entire biotech sector has suffered under the 
uncertainty of what potential regulations may mean for future biotech revenues. 
 
 
                                                        
20 Juno Therapeutics. (December 5th, 2016). Juno Therapeutics Presents Data from TRANSCEND Study Showing 60% 
Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma. [Press 
Release]. Retrieved from: http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-newsArticle&ID=2227607 
21 Bluebird Bio. (November 30th, 2016). bluebird bio Announces Interim Phase I Dose Escalation Data for its Anti-
BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma. [Press Release]. Retrieved 
from: http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2226688 
22 Kite Pharma Inc. (October 18th, 2016) Investor Day: Focused on the Cure. Slide 24.  





Figure 5.  Kite Pharma (Nasdaq: KITE) stock performance (white line) since they went public on June 20th, 2014 
(Source: Bloomberg Terminal; Command <GP>; Accessed 12-8-16) 
  
Compared to the S&P 500 and the S&P 600 Health Care Index, Kite Pharma has 
underperformed over the last year (Figure 6).  However, this is not surprising or 
unexpected for a pre-profit biotechnology company where one data release is enough 




Figure 6.  Kite Pharma (Nasdaq: KITE) stock performance (white line) compared to the S&P 500 (purple line) and the 
S&P SmallCap 600 Health Care Index (orange line) 
(Source: Bloomberg Terminal; Command <GP>; Accessed 12-8-16) 
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Since Kite Pharma has not yet brought any of its T-cell therapies to market yet, 
they have not generated significant revenues.  To date their revenues have come solely 
from their partnerships with other companies.  As a result their earnings per share (EPS) 




Figure 7.  Kite Pharma (Nasdaq: KITE) Revenue Growth and Earnings Per Share (EPS) 
(Source: Bloomberg Terminal; Command <DES>; Accessed 12-8-16) 
 
Pre-Profit Biotechnology Model: 
 
 We have created a proprietary discounted net present value (NPV) model for 
determining the valuation of a pre-profit biotechnology company.  Using this model, we 
can estimate the revenues expected from a drug in the event of FDA approval and weigh 
this outcome against a reasonable probability of failure.  Our model for Kite Pharma 
accounts for its lead product (KTE-C19) in three potential approval settings: FDA 
approval for treatment of relapsed/refractory DLBCL23, EMA approval for 
relapsed/refractory DLBCL, and FDA approval for adult and pediatric relapsed/refractory 
ALL.  We chose to only include this drug candidate for these indications since Kite 
Pharma’s other products are currently not developed enough to accurately evaluate 
their potential for success.  However, it is worth noting that Kite Pharma has numerous 
promising products in their pipeline that could progress to completion within the 
timeline of our model (Figure 1).  Therefore, we may be understating potential earnings.  
 In addition to our NPV model, we have simulated the probability of drug 
approval based on the clinical stage that the drug is currently being evaluated at.  For 
                                                        
23 For the purposes of our model, we are incorporating the extremely small PMBCL and TFL patient population into 
the larger population of DLBCL patients.  
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example, a drug that has successfully completed a Phase 3 clinical trial is more likely to 
become FDA approved than a drug that is still undergoing Phase 1 evaluation.  By 
attributing probabilities calculated from historical drug approval rates at each stage of 
drug development, we can model a distribution that includes the chances of both drug 
success and failure and arrive at a more accurate representation of the fundamental 
value of the company.24  Using a Monte Carlo simulation, we have considered the 
probability of regulatory approval in the context of the potential revenues projected by 
our NPV model and obtained a multimodal distribution that reflects the range of 
possible market share prices depending on the success of KTE-C19.25  By comparing our 
distribution to the current stock price we can assess whether the market is discounting a 
realistic probability of success or not. 
The core of our model was built with primary data from SEC filings from the last 
three fiscal years since the company’s inception (FY2013-FY2015).  Quarterly filings from 
the first three quarters of 2016 were included for projecting FY2016 data.   
 
Income Statement and Balance Sheet Trends: 
These results are contained on the “Balance Sheet” and “Income Statement” tabs of the accompanying spreadsheet 
  
 Kite Pharma recorded $17.3 million in revenues in FY2015, and is expected to 
record  approximately $22.5 million in FY2016.26  These revenues are generated solely 
from partnerships, particularly with Amgen, since Kite Pharma has not yet 
commercialized any of its T-cell therapies.   
 On the balance sheet, there is a steady decline in cash and total assets 
throughout the first three quarters of 2016.  At the time of this writing, Kite Pharma has 
reported $477.1 million in cash and investments.  The company has averaged a net burn 
rate of $62.3 million per quarter in 2016. Assuming they maintain this level of spending 
until the first FDA approval and launch of KTE-C19, Kite Pharma currently has a runway 
of approximately 7 quarters, or 21 months.  This is in line with management’s estimate 
that current cash holdings will be sufficient to carry the company until mid-way through 
2018. If the FDA approval and/or launch of KTE-C19 are delayed for any reason, Kite 
Pharma could be forced to take on debt to support operations.  Currently, the company 
is debt free.   
There is a notable increase in long-term assets in FY2015 that reflects the stock 
purchase agreement of T-Cell Factory (TCF), renamed Kite Pharma EU B.V., and the 
construction of El Segundo, the state-of-the-art commercial T-cell therapy 
manufacturing facility.  It is worth noting that Kite Pharma is required to pay up to 
€242.5 million to TCF upon achieving certain clinical, regulatory, and sales goals.  These 
payments were not factored into our model since they only apply to TCR products, 
which are still in the earlier stages of development.  However, these payments may 
                                                        
24 Keegan, K. Biotechnology Valuation: An Introductory Guide. England: John Wiley and Sons 2008; pg. 40 
25 Program: Crystal Ball by Oracle  
26 Consensus from the Bloomberg Terminal as of December 8th, 2016 
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come into play in the later years of our model and may cause erosion to Kite Pharma’s 
revenues.  
 
Modeling FDA Regulatory Approval: 
These results are contained on the “Alpha-Beta Values” and “Revenue Growth Projections” tabs of the accompanying 
spreadsheet 
 
In order for a new drug to be brought to market, it must pass through four 
stages: discovery and development, pre-clinical research, clinical research, and FDA 
review.27  If a drug becomes FDA approved, it moves into stage five where the drug 
continues to be monitored for safety.  The probability that a drug will reach the market 
can be assessed once it reaches the clinical research stage (Table 1).  As a drug 
successfully progresses from one phase of clinical trials to the next, the expected 




Table 1. The Probability that the FDA will Approve a Drug is Dependent Upon its Stage in Clinical Research 
(Source: Keegan, K. Biotechnology Valuation: An Introductory Guide. England: John Wiley and Sons 2008; pg. 40) 
 
Using these probabilities, we can model the likelihood that the FDA will approve 
a new drug using a continuous probability distribution, specifically a beta distribution.28  
Beta distributions are defined by the interval [0,1], and are influenced by the shape 
parameters denoted α and β.  Here, we used the probability density function with a 





0,      𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 𝑓𝑓𝑜𝑜ℎ𝑒𝑒𝑓𝑓𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
 𝑓𝑓𝑓𝑓𝑓𝑓 0 < 𝑥𝑥 < 1 
 





Solving for the expected value (mean) and variance of this distribution gives us: 
 
                                                        
27 U.S. Food and Drug Administration. (June 24th, 2015). The Drug Development Process. Retrieved from: 
http://www.fda.gov/forpatients/approvals/drugs/default.htm 
28 Wackerly, D. D., Mendenhall, W., and Scheaffer, R. L.  Mathematical Statistics with Applications.  6th Edition (2001).  
Dusbury Press. 
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𝑉𝑉𝑏𝑏𝑓𝑓(𝑋𝑋) = 𝜎𝜎2 =
𝛼𝛼𝛽𝛽
(𝛼𝛼 + 𝛽𝛽)2(𝛼𝛼 + 𝛽𝛽 + 1)
 
 
Since a rolling BLA for KTE-C19 has been submitted to the FDA to treat 
relapsed/refractory DLBCL, we can define the expected (average) probability of success 
of KTE-C19 becoming FDA approved for relapsed/refractory DLBCL to be 90% (the mean 








� 𝜇𝜇2 = 7.2 
 
𝛽𝛽 = 𝛼𝛼 �
1
𝜇𝜇
− 1� = 0.8 
 
These values for α and β generate the beta distribution shown in Figure 8. 
Although this probability distribution appears optimistic, we are firm believers in the 




Figure 8.  Beta Distribution for a 90% probability that KTE-C19 will be FDA approved for relapsed/refractory DLBCL 
(Source: “Monte Carlo Simulation” tab of the accompanying spreadsheet) 
 
Our model also takes into account the potential for KTE-C19 to be approved by 
the EMA for relapsed/refractory DLBCL, as well as another FDA approval for the use in 
adult and pediatric relapsed/refractory ALL.  For these, we can assign the probability for 
EMA approval for DLBCL at 60% based on the Phase 2/3 status of the ZUMA-1 clinical 
trial, and a probability of 25% for FDA approval for ALL based on Phase 1 status for the 
ZUMA-3 and ZUMA-4 clinical trials.  The α and β values used and graphs of each beta 
distribution are included in Appendix B.  
 Next, it is necessary to assign a uniform distribution that will generate a random 
variable between 0 and 1 and a separate binary cell that is capable of only taking the 
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values of 1 (drug success) or 0 (drug failure).  This will change the NPV of our model 
depending on whether the drug succeeds or fails by multiplying the two values 
depending on the probabilities defined from our beta distributions.  Using this method 
in a Monte Carlo simulation, we can create a distribution for the estimated stock price 
depending upon the success or failure of the drug for each of the indications.   
 For Kite Pharma, we are considering the approval of KTE-C19 for three 
indications.  Therefore, we have incorporated three separate beta distributions into our 
model.  
 
Revenue Growth Projections: 
These results are contained on the “Historical Population Growth” and “Revenue Growth Projections” tabs of the 
accompanying spreadsheet 
 
 In order to estimate the potential revenue generated from KTE-C19 sales, it is 
necessary to determine the size of the target population and the potential market share 
of that population we expect KTE-C19 to achieve each year for each of its indications.  
We do this using a top-down, or waterfall, approach detailed below: 
 
1. Modeling the U.S./E.U.-5 Population: First, it is necessary to model the total 
population growth for both the U.S. and the E.U.-5 (United Kingdom, France, 
Spain, Germany, Italy) for the next 10 years.  To do this, we used census data and 
calculated the year-over-year historical population growth for paired consecutive 
years.  Taking the average of these, we can define the historical population 
growth rates to be 0.79%29 for the U.S. and 0.37%30 for the E.U.-5.  We use these 
historical growth rates to project the total population for the next 10 years in our 
model.  
2. Modeling the Population with Relapsed/Refractory DLBCL or ALL:  The next 
step is to determine the total population that exhibits the disease being treated.  
For DLBCL in the U.S., we first calculated the population that has been diagnosed 
with NHL, which is 0.022% of the total U.S. population.31  Of those with NHL, 
approximately 35% of patients are diagnosed with DLBCL.32  From these patients, 
approximately 40% will develop relapsed/refractory disease.33  For DLBCL in the 
                                                        
29 Data for the U.S. population was obtained from the census bureau.  Data retrieved from: 
http://www.multpl.com/united-states-population/table 
30 Data for the E.U.-5 population was obtained from data provided by Statista.  The yearly populations from each 
country in the E.U.-5 were summed and the average growth rate was obtained.  The data were retrieved from: 
https://www.statista.com/statistics/611363/population-of-europe-by-country/ 
31 In 2016, the NIH SEER program estimated 72,580 new cases diagnosed of DLBCL.  This is approximately 0.022% of 
the US population, and this value was therefore used as the rate of new diagnoses for our model.  The data were 
retrieved from: https://seer.cancer.gov/statfacts/html/nhl.html 
32 Consensuses vary, but most sources agree the rate of DLBCL is between 30-40% of all NHL cases.  We chose to take 
the average of this range, 35%, for our model.  Representative Source: Roschewski, M. et al. Diffuse large B-cell 
lymphoma- treatment approaches in the molecular era. Nat Rev Clin Onc. 11, 12-23 (2014).  
33 Similar to above, consensuses vary.  We choose to use a rate of 40% for our model.  Representative Source: 
Freidber, J. W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am. Soc. Hematol. Educ. Program. 
2011, 498-505 (2011).  
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E.U.-5, approximately 0.007% of the population is diagnosed with DLBCL34, and 
40% of this population will develop relapsed/refractory disease.35  For ALL in the 
U.S., approximately 0.002% of the population is diagnosed with ALL36, and 20% 
of this population will develop relapsed/refractory disease.37   
3. Determining the Market Share the Drug is Expected to Obtain: Once the target 
population has been determined, the next step is to assign the percentage of 
that market that the drug is expected to achieve.  For KTE-C19, we expect a 
relatively low market penetration due to manufacturing constrictions and severe 
side effects, especially right after regulatory approval.  In the initial year of 
launch, we have conservatively estimated that the market penetration will be 
0.1% for DLBCL and 0.5% for ALL.  From here, we expect the market penetration 
to increase by 2% each year.  We chose to conservatively project KTE-C19’s 
market penetration because the immunotherapy field is becoming increasingly 
crowded, and competition from companies developing monoclonal antibodies 
and similar CD19 CAR T-cell therapies will erode revenues as additional drugs 
become approved for the same populations.  Therefore, it is possible that our 
conservative approach has undervalued the revenue growth for Kite Pharma.  To 
balance our moderate projections, however, we set a uniform distribution for 
market penetration to increase by 2-4% in our Monte Carlo simulation.  
4. Estimating the Cost of the Drug:  Lastly, we must estimate the cost of the drug.  
Since there are no similar therapies on the market, we chose to use the costs of 
stem cell transplants for comparison.  Autologous stem cell transplants can cost 
anywhere between $200-$500k and allogeneic stem cell transplants can cost 
upwards of $900k.38  Based on these values, we chose to set our price at $400k 
per treatment, with a uniform distribution ranging from $300-$550k in our 
Monte Carlo simulation.  
 
By multiplying the target population by the expected market penetration rate 
and the cost of the drug, we can estimate the potential revenue generated for that year.  
Summing the revenues for each of the indications gives the total estimated revenue for 
the company per year based on the sales of KTE-C19.  
Lastly, it is important to consider the timeline for FDA approval in each of the 
indications (Table 2).  In the best-case scenario, KTE-C19 could become FDA approved in 
                                                        
34 In their 2016 Investor Day presentation, Kite Pharma cited data indicating 22,000 new cases of DLBCL diagnosed in 
the E.U.-5 in 2016.  This is approximately 0.007% of the total E.U.-5 population calculated above, and this value was 
therefore used for our model.  Source: Kite Pharma Inc. (October 18th, 2016) Investor Day: Focused on the Cure. Slide 
100. 
35 Tilly, H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann. Oncol. 26 (Supplement 5), v116-v125 (2015).  
36 In 2016, the NIH SEER program estimated 6,590 new cases diagnosed of ALL. This is approximately 0.002% of the 
U.S. population, and this value was therefore used as the rate of new diagnoses for our model.  The data were 
retrieved from: https://seer.cancer.gov/statfacts/html/alyl.html 
37 Raetz, E. A. and Bhatla, T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? 
Hematology Am. Soc. Hematol. Educ. Program. 2012, 129-136 (2012).  
38 Kite Pharma Inc. (October 18th, 2016) Investor Day: Focused on the Cure. Slide 114. 
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the quarter four of 2017.  If the BLA is delayed, it could delay the launch date to 




Table 2.  Timeline for Expected Launch of KTE-C19 for Each of the Projected Indications 
(Source: “Revenue Growth Projections” and “Pipeline” tabs of the accompanying spreadsheet) 
 
Expense Projections: 
These results are contained on the “Revenue Growth Projections” tab of the accompanying spreadsheet 
  
 In order to project expenses over the next 10 years, we looked at each expense 
individually and calculated the year-over-year growth for the available three years of 
historical data.  However, these values varied widely, making it difficult to accurately 
project these costs.  Using the three quarterly reports for 2016, we were able to project 
the expected growth rate for R&D and General & Administrative Costs for FY2016 to be 
140% and 50%, respectively.  Since Kite Pharma is currently operating numerous clinical 
trials while simultaneously developing additional pre-clinical products in their pipeline, 
we expect their R&D costs to continue to climb, and assigned 100% growth rates for 
2017E and 2018E.  From 2019E on, we dropped this rate to 50%.   
Since we expect that KTE-C19 will be FDA approved and launched in late 2017, it 
is necessary to separate Selling Costs out from General & Administrative Costs.  We 
therefore assigned a growth rate of 15% for General & Administrative Costs and a 25% 
for Selling Costs for all projected 10 years.  By summing these values, we arrive at a 
reasonable growth margin of 25-26% for all projected years for total Selling, General & 
Administrative Costs.  Lastly, we assigned a 25% growth rate for Costs of Goods Sold. 
 The expenses for the next 10 fiscal years were projected using these growth 
rates.  We next calculated the Operating Income by subtracting these expenses from the 
total projected revenue and assigned the estimated tax rate to be 25%.  Since Kite 
Pharma is not expected to pay royalties on KTE-C19 sales, we set this parameter to 
0%.39  From here, we calculated the expected net income for each year using the 
equation below.  
 
𝑁𝑁𝑒𝑒𝑜𝑜 𝐼𝐼𝑓𝑓𝑓𝑓𝑓𝑓𝐼𝐼𝑒𝑒 = 𝑂𝑂𝑝𝑝𝑒𝑒𝑓𝑓𝑏𝑏𝑜𝑜𝑒𝑒𝑓𝑓𝑒𝑒 𝐼𝐼𝑓𝑓𝑓𝑓𝑓𝑓𝐼𝐼𝑒𝑒 − �(𝑂𝑂𝑝𝑝𝑒𝑒𝑓𝑓𝑏𝑏𝑜𝑜𝑒𝑒𝑓𝑓𝑒𝑒 𝐼𝐼𝑓𝑓𝑓𝑓𝑓𝑓𝐼𝐼𝑒𝑒 ∗ 𝑇𝑇𝑏𝑏𝑥𝑥 𝑅𝑅𝑏𝑏𝑜𝑜𝑒𝑒) + (𝑅𝑅𝑓𝑓𝑅𝑅𝑏𝑏𝑅𝑅𝑜𝑜𝑒𝑒𝑒𝑒𝑒𝑒 ∗ 𝑅𝑅𝑒𝑒𝑅𝑅𝑒𝑒𝑓𝑓𝑓𝑓𝑒𝑒)� 
  
                                                        
39 Kite Pharma is not obligated to pay royalties on KTE-C19, but the company has made partnerships for some of its 
other products that require royalty payments, particularly its MAGE A3/A6 and HPV E6/E7 TCR products.  These 
products were not included in our model due to lack of clinical data, and are therefore excluded when calculating Kite 
Pharma’s projected net income. 
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Net Present Value (NPV) Model: 
These results are contained on the “Revenue Growth Projections” tab of the accompanying spreadsheet 
 
 In order to estimate the target share price, we used the Net Present Value (NPV) 




(1 + 𝐷𝐷𝑒𝑒𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜 𝑅𝑅𝑏𝑏𝑜𝑜𝑒𝑒)𝑡𝑡
 
 
𝑒𝑒ℎ𝑒𝑒𝑓𝑓𝑒𝑒 𝑜𝑜 = 𝑜𝑜ℎ𝑒𝑒 𝑓𝑓𝑓𝑓𝐼𝐼𝑏𝑏𝑒𝑒𝑓𝑓 𝑓𝑓𝑓𝑓 𝑅𝑅𝑒𝑒𝑏𝑏𝑓𝑓𝑒𝑒 𝑝𝑝𝑏𝑏𝑒𝑒𝑒𝑒𝑒𝑒𝑑𝑑 
 
For year 10, we used the NPV Terminal Value equation with a discount rate of 
10% and a residual growth rate of 1.5%. 
 
𝑁𝑁𝑉𝑉𝑁𝑁 𝑓𝑓𝑓𝑓𝑓𝑓 2026 =
𝑁𝑁𝑒𝑒𝑜𝑜 𝐼𝐼𝑓𝑓𝑓𝑓𝑓𝑓𝐼𝐼𝑒𝑒2026
(𝐷𝐷𝑒𝑒𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜 𝑅𝑅𝑏𝑏𝑜𝑜𝑒𝑒 − 𝑅𝑅𝑒𝑒𝑒𝑒𝑒𝑒𝑑𝑑𝑓𝑓𝑏𝑏𝑅𝑅 𝐺𝐺𝑓𝑓𝑓𝑓𝑒𝑒𝑜𝑜ℎ 𝑅𝑅𝑏𝑏𝑜𝑜𝑒𝑒) ∗ (1 + 𝐷𝐷𝑒𝑒𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜 𝑅𝑅𝑏𝑏𝑜𝑜𝑒𝑒)9
 
 
By summing the NPV for all projected 10 years and dividing by the shares 
outstanding, we determined the target NPV/share for Kite Pharma to be $85.30. 
 






These results are contained on the “Monte Carlo Simulation” and “Monte Carlo Figures” tabs of the accompanying 
spreadsheet 
 
 In our model for Kite Pharma we have made assumptions for the timeline for 
drug approval (and therefore revenue generation), drug pricing, market penetration, 
and expenses.  Assuming regulatory approval for KTE-C19 in all three of the indications 
considered, we have identified a target price of $85.30 with an 89.25% potential upside 
over the current stock price of $45.07 for Kite Pharma.41 
 Since regulatory approval is not guaranteed, we performed a Monte Carlo 
simulation to account for the possibilities of both drug success and failure.  The 
simulation takes into account the probability for drug approval based on the clinical 
stage of development, as well as uncertainties in the achievable market penetration rate 
and drug pricing.  The distribution generated from this simulation was multimodal, with 
a mean price of $91.74 and an upside of 103.55% (Figure 9). 42  The current stock price 
of $45.07 is in the 19th percentile, indicating that Kite Pharma is extremely undervalued 
and that the market is assigning a high probability of failure.  This should come as no 
surprise given the nascent nature of the therapy, however, we firmly believe that the 
                                                        
40 A discount rate of 10% was chosen over Kite Pharma’s WACC of 10.8% since our model is designed to reflect the 
investor’s opportunity cost, rather than the company’s (since WACC is constantly changing, it inherently reflects only 
the company’s opportunity cost).  By contrast, 10% reflects the average rate of return from the S&P 500, and is 
therefore more reflective of the investor’s opportunity cost.   
41 At the time of this writing: December 8th, 2016. 
42 At the time of this writing: December 8th, 2016. 
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pipeline is undervalued based on our analyses.  Indeed, the target price of $85.30 
generated by our proprietary NPV model is in the 48th percentile of the simulation, 




Figure 9.  The Monte Carlo Simulation Predicts a Mean Share Price of $91.74 for Kite Pharma (Nasdaq: KITE) 
The Monte Carlo simulation was run for 100,000 trials.  The left panel shows the probability distribution, with the blue values 
indicating the probability below the current stock price and the pink values indication the probability above the current stock 
price.  The right panel shows descriptive statistics for the simulation. 
 
The wide distribution in share prices ranging from -$39.70 to $447.52 in the 
Monte Carlo simulation is a result of a number of ambiguities expected for a pre-profit 
biotechnology company.  In order to differentiate which factors are due to the 
sensitivity of the model and which are based on uncertainties in our assumptions, we 
performed a sensitivity analysis (Figure 10).   
Some of the most influential factors found in the sensitivity analysis are 
expected, including the yearly growth in market penetration and the random number 
generator that simulated whether KTE-C19 was FDA approved or not.  However, there 
were three factors that contributed greatly to the shape of the distribution that result 
from uncertainties in our assumptions within the last year in our model: the percentage 
of newly diagnosed NHL patients in the US (cell M27), the growth rate for Selling Costs 
(cell M88), and the growth rate of Cost for Goods Sold (cell M94).  When these values 
are excluded, the results of the simulation change only minimally (mean of $91.96), but 
the range of the distribution tightens slightly to -$28.44 to $253.90 (Figure 11).  The high 
degree of uncertainty that remains in the distribution is not surprising for a pre-profit 
biotechnology company. 
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Overall, our NPV model and Monte Carlo simulation predict a target price that is 
significantly higher than what is being reflected currently in the market.  The most likely 
reason for this discrepancy is the under appreciation of the potential for engineered T-
cell therapies to drive revenues and the uncertainty of whether they will gain FDA 
approval.  We disagree with this outlook and believe Kite Pharma has an excellent 
chance of commercializing its lead product KTE-C19.  The company has presented 
compelling data indicating efficacy in clinical trials, is the first to submit a BLA to the 
FDA, and has the advantage of pricing power with a novel therapy targeting a small 




Figure 10.  Sensitivity Analysis Applied to the Monte Carlo Simulation in Figure 9  
Of the top influencers, newly diagnosed NHL patients in year 10 (M27), the growth rate for Selling Costs in year 10 (M88), and 
the growth rate for Cost of Goods Sold in year 10 (M94) were excluded due to relevance.  The random number generator for 
the probability of FDA approval (B56 and B38), the beta distributions for KTE-C19 approval in R/R DLBCL for the FDA (B37) and 
the EMA (B55), and the yearly growth for market penetration (B18) are metrics that we would expect to drive the distribution 
of the simulation, and were therefore left intact.  Additionally, we also elected to leave the percentage of refractory DLBCL 
patients in year 10 (M31), the cost of KTE-C19 in year 10 (M32) and the percent of patients with NHL that are diagnosed with 
DLBCL in year 10 (M29) intact since the correlation was below 2%.  
 
 





Figure 11.   Sensitivity Analysis Adjusted Monte Carlo Simulation Predicts a Mean Share Price of $91.91 for Kite Pharma 
(Nasdaq: KITE) 
Newly diagnosed NHL patients in year 10 (M27), the growth rate for Selling Costs in year 10 (M88), and the growth rate for Cost 
of Goods Sold in year 10 (M94) were excluded from the simulation due to relevance.  The simulation was run for 100,000 trials.  
The left panel shows the probability distribution, with the blue values indicating the probability below the current stock price 





To assess management’s incentives and whether it is aligned with our 
investment thesis, we performed an analysis of the proxy statement and critically 




 Dr. Arie Belldegrun, M.D. founded Kite Pharma in 2009 and serves as its 
Chairman, President, and CEO. Dr. Belldegrun pioneered some of the early T-cell therapy 
work while completing his fellowship at the National Cancer Institute under the 
mentorship of Dr. Steven Rosenberg.  In 1996 he founded Agensys and served as its 
Chairman of the Board of Directors from 1996-2002 and then as its Director until 
Astellas Pharma acquired the company in 2007.  Dr. Belldegrun also served as the 
founding Vice Chairman of Cougar Biotechnology from 2003 until 2009 when Johnson & 
Johnson acquired it.  Since then, Dr. Belldegrun has focused his expertise on developing 
a robust pipeline for Kite Pharma and ensuring the company is prepared for 
commercializing its leading product KTE-C19. Based on his prior experience and current 
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efforts within Kite Pharma, we believe the Dr. Belldegrun has the capacity to move the 
company forward in a manner that will increase shareholder value.   
 Since going public in 2014, Kite Pharma has worked to expand its management 
team. The current management officers and their experience in top pharmaceutical and 
biotechnology companies are detailed in Figure 12.  Collectively, they boast experience 
from within top pharmaceutical companies and successful biotech companies.  As a 





Figure 12. Kite Pharma (Nasdaq: KITE) Management Team   




Kite Pharma’s executive compensation plan is composed of three main parts:   
1. Annual Base Salary 
2. Annual Bonus Opportunity 
3. Long-Term Incentive Compensation 
 
Annual Base Salary: 
 
 The base salaries for the named executive officers are listed in Figure 13.  These 
salaries are awarded on the basis of the executive officer’s ability to lead and organize 
others, recognize new business opportunities, and to help Kite Pharma grow and 
succeed.  The annual base salaries are compared to the benchmark companies listed in 
Table 3 to ensure that they are competitive.  
 






Figure 13. Executive Officers 2015 Base Salary  




Table 3. 2015 Benchmark Peer Group 
(Source: Kite Pharma Inc. DEF-14A 2016) 
 
Annual Bonus Opportunities: 
  
 An annual bonus is awarded to individual executives based on their contribution 
toward the annual corporate goals.  The goals set for FY2015 are outlined in Table 4.  
The amount awarded to each executive is based on how successfully these goals were 
achieved.  Kite Pharma’s management was able to meet and exceed the goals set for 
FY2015, and the executives were therefore awarded the amounts shown in Table 5.   
   
 
 
Table 4. Annual Bonus Opportunity Goals for FY2015  
(Source: Kite Pharma Inc. DEF-14A 2016) 






Table 5. Executive Officers 2015 Annual Bonus Award  
(Source: Kite Pharma Inc. DEF-14A 2016) 
 
Long-Term Incentive Compensation: 
 
  Long-term incentive compensation is granted in the form of equity awards, both 
common shares and restricted stock units.  Executive officers are awarded stock options 
when they are first hired, and thereafter at the discretion of the compensation 
committee.  Equity awards may be granted when an officer is promoted, or to award 
exceptional performance.  Executive officers are eligible to receive a mix of 70% 
common shares and 30% restricted stock units, which vest 25% annually over four years.  
Currently, none of the officers have a contract that dictates they will receive stock 
options annually, making these awards solely performance based.  All named executives 




Figure 14.  Long-Term Incentive Compensation  
(Source: Kite Pharma Inc. DEF-14A 2016) 
 
 Overall, the executive’s compensation plan appears balanced and designed to 
increase shareholder value given the specific goals of progressing the pipeline and 
achieving FDA approval (Table 4).  The base salaries are evaluated against a comparable 
group of peer benchmark companies and the annual bonus opportunity awards are 
connected to a series of goals designed to propel the company forward.  The long-term 
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incentive plan could benefit from a similar list of long-term goals that management 
expects to achieve.  This would help shareholders determine where the company sees 
itself in the future and would encourage management to outline how they hope to 
achieve these goals.  Figure 15 shows a summary of management’s compensation for 




Figure 15.  Overview of Executive Compensation 
(Source: Kite Pharma Inc. DEF-14A 2016) 
 
Insider Shareholders and Trading: 
 
There are no surprises or red flags when we look at the top shareholders for Kite 
Pharma (Figure 16).  The CEO, Dr. Arie Belldegrun, is the 7th top shareholder and owns 
approximately 4.68% of shares.  This is an encouraging sign, indicating that the CEO 
believes strongly in the company’s ability to bring their products to market.  Similarly, 
there are no insider trades that indicate management is losing faith in the company’s 
ability to succeed (Figure 17).   
 





Figure 16.  Kite Pharma’s (Nasdaq: KITE) Top Institutional and Insider Shareholders 





Figure 17.  Kite Pharma’s (Nasdaq: KITE) Recent Insider Transactions 
(Source: Bloomberg Terminal; Command <GPTR>; Accessed 12-8-16) 
 





 Using a proprietary discounted net present value (NPV) model along with market 
insights, we have concluded that Kite Pharma is undervalued with a potential upside of 
89.25% based on the target price of $85.30.  We recognize that there is uncertainty 
regarding the FDA approval process and there is no guarantee that KTE-C19 will become 
FDA or EMA approved for any of the indications included in the model.  However, we 
have accounted for the risk of failure by conducting a Monte Carlo simulation using the 
historical probabilities of success based on the clinical stage of the FDA approval process 
for each of the indications.  Thus, KITE represents an investment with significant risk-
reward asymmetry.  Additionally, Kite Pharma’s management team is highly 
experienced with an excellent track record of bringing products to market.  The 
company’s management compensation plan appears to be balanced and sufficiently 
aligned with shareholder value creation.  Additionally, management has recently made 
smart capital allocation decisions to ensure that Kite Pharma maintains a robust drug 
pipeline and is prepared for the commercialization of KTE-C19 immediately upon its 
anticipated FDA approval in late 2017. 
 Based on these findings, we recommend Kite Pharma, Inc. a BUY with a target 
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Table 6.  List of Kite Pharma’s (Nasdaq: KITE) Collaborations and Agreements, and a Brief Description of the 
Objective of Each Partnership 













Table 7.  The Values α and β Used to Generate the Beta Distributions for KTE-C19 




Figure 18.  Beta Distribution for a 90% Probability that KTE-C19 will be FDA Approved for DLBCL 
(Generated by Crystal Ball) 
 
 





Figure 19.  Beta Distribution for a 60% Probability that KTE-C19 will be EMA Approved for DLBCL 





Figure 20.  Beta Distribution for a 25% Probability that KTE-C19 will be FDA Approved for ALL 
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Figure 21.  Analyst Recommendations for Kite Pharma (Nasdaq: KITE) 
(Source: Bloomberg Terminal; Command <ANR>; Accessed 12-8-16) 
 
 
 
